Scopolamine - Isotope Labelled Standards
References
FAQ's
References
- Solomon, Mark J.; Crane, Frank A.; Chu, B. L. Wu; Mika, E. S., Simultaneous quantitative gas-chromatographic determination of atropine and scopolamine, Journal of Pharmaceutical Sciences, Volume: 58, Issue: 2, Pages: 264-6, 1969
- Chu, B. L. Wu; Mika, Edward S., Use of tetraphenylethylene in quantitative GLC [gas-liquid chromatography] of hyoscyamine and scopolamine, Journal of Pharmaceutical Sciences Volume: 59, Issue: 10, Pages: 1508-10, 1970, DOI: (https://doi.org/10.1002/jps.2600591034)
Frequently Asked Questions
Are Scopolamine impurities harmful?
The existence of impurities does not always signify danger as long as their nature and levels are under strict control. The setting of impurity levels is based on safety and efficacy considerations. Impurity levels must be within acceptable range to reduce potential adverse effects.
Can impurities in Scopolamine affect its effectiveness?
Impurities in Scopolamine can affect its effectiveness by altering the drug's pharmacokinetics, pharmacodynamics, or stability. Manufacturers aim to control impurities so the drug maintains its potency and delivers the desired therapeutic outcomes.
How are Scopolamine impurities detected and quantified?
Analytical techniques such as high-performance liquid chromatography with ultraviolet detection help detect and quantify Scopolamine impurities. These methods enable accurate identification and measurement of impurity levels.
What are the temperature conditions required to store Scopolamine Impurities?
Scopolamine Impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.